RHEUMATOLOGY

Prolia 60 mg

Availability:

Manufacturer:

Amgen Inc.

Prolia® 60 mg 1 syringe (Denosumab)

Prolia® contains denosumab, a protein (monoclonal antibody) that interferes with the action of another protein, in order to treat bone loss and osteoporosis. Treatment with Prolia® makes bone stronger and less likely to break.

Bone is a living tissue and is renewed all the time. Oestrogen helps keep bones healthy. After the menopause, oestrogen level drops which may cause bones to become thin and fragile. This can eventually lead to a condition called osteoporosis. Osteoporosis can also occur in men due to a number of causes including ageing and/or a low level of the male hormone, testosterone. It can also occur in patients receiving glucocorticoids. Many patients with osteoporosis have no symptoms, but they are still at risk of breaking bones, especially in the spine, hips and wrists.

Surgery or medicines that stop the production of oestrogen or testosterone used to treat patients with breast or prostate cancer can also lead to bone loss. The bones become weaker and break more easily.

Prolia®  is used to treat:

 - osteoporosis in women after the menopause (postmenopausal) and men who have an increased risk of fracture (broken bones), reducing the risk of spinal, non-spinal and hip fractures.

- bone loss that results from a reduction in hormone (testosterone) level caused by surgery or treatment with medicines in patients with prostate cancer.

- bone loss that results from long-term treatment with glucocorticoids in patients who have an increased risk of fracture.

Do not use Prolia®

if you have low calcium levels in the blood (hypocalcaemia);

if you are allergic to denosumab or any of the other ingredients of this medicine

Similar products